市場調查報告書
商品編碼
1416202
藥物洗脫球囊導管市場規模-按產品[冠狀動脈和周圍血管疾病導管(紫杉醇、西羅莫司)]、材料(聚氨酯、尼龍)、最終用途和全球預測,2023-2032 年Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032 |
藥物洗脫球囊導管市場預計從 2023 年到 2032 年將以 11.5% 的CAGR擴張。全球心血管疾病盛行率不斷上升,對有效治療方案的需求不斷增加。
醫療技術的不斷進步和創新導管設計的發展正在提高藥物洗脫球囊手術的功效,吸引了患者和醫療保健提供者。例如,2022 年 5 月,美敦力 (Medtronic) 的 IN 獲得 FDA 批准。 PACT 018 紫杉醇塗層 PTA 球囊導管,一種藥物塗層球囊 (DCB),用於介入治療股淺動脈和膕動脈周圍動脈疾病 (PAD)。此外,人口老化的加劇導致冠狀動脈疾病的發生率增加,進一步刺激了藥物洗脫球囊導管的需求。此外,有利報銷政策的湧入以及政府支持採用先進醫療設備的舉措的增加將推動市場成長。
藥物洗脫球囊導管市場按產品、材料、最終用途和地區分類。
根據產品,冠狀動脈疾病藥物洗脫球囊導管領域的市場價值預計在 2023 年至 2032 年間將以 11.8% 的CAGR成長。這一成長可歸因於冠狀動脈疾病患病率的增加和導管技術的不斷進步。對微創治療方案的需求不斷增加也將推動該細分市場的成長。
預計 2023 年至 2032 年,尼龍材料領域的藥物洗脫球囊導管市場佔有率複合CAGR為 11.4%。這是由於尼龍為導管結構提供了有利的特性,包括靈活性和耐用性。此外,尼龍的生物相容性及其在血管成形術過程中有效輸送藥物的能力將增強藥物洗脫球囊導管的整體性能。
從區域來看,亞太地區藥物洗脫球囊導管產業規模預計從 2023 年到 2032 年將以 14.6% 的CAGR擴大。這種成長可歸因於心血管疾病盛行率的不斷上升、對微創治療方案的認知不斷提高以及完善的微創治療方案。醫療保健基礎設施。不斷擴大的患者群體導致人們越來越關注改善醫療保健的可近性。此外,醫療技術的不斷進步和政府的有利措施將加速區域產品需求。
Drug-eluting balloon catheters market is projected to expand at 11.5% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases across the globe is escalating the demand for effective treatment options.
The rising advancements in medical technologies and the development of innovative catheter designs is enhancing the efficacy of drug-eluting balloon procedures, attracting both patients and healthcare providers. For instance, in May 2022, Medtronic received the FDA approval for the IN. PACT 018 Paclitaxel-Coated PTA balloon catheter, a drug-coated balloon (DCB) for interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. Additionally, the growing aging population is contributing to the increased incidences of coronary artery diseases, further fueling the demand for drug-eluting balloon catheters. Moreover, the influx of favorable reimbursement policies and the rise in government initiatives for supporting the adoption of advanced medical devices will boost the market growth.
The drug-eluting balloon catheters market is segregated into product, material, end-use, and region.
Based on product, the market value from the coronary artery disease drug eluting balloon catheters segment is projected to rise at 11.8% CAGR between 2023 to 2032. The growth can be attributed to the increasing prevalence of coronary artery diseases and the rising advancements in catheter technologies. The heightening demand for minimally invasive treatment options will also drive the segment growth.
Drug-eluting balloon catheters market share from the nylon material segment is estimated to witness 11.4% CAGR from 2023 to 2032. This is due to the favorable properties offered by nylon for catheter construction, including flexibility and durability. Moreover, the biocompatibility of nylon coupled with its ability to effectively deliver drugs during angioplasty procedures will enhance the overall performance of drug-eluting balloon catheters.
Regionally, the Asia Pacific drug eluting balloon catheter industry size is projected to expand at 14.6% CAGR from 2023 to 2032. The growth can be attributed to the growing prevalence of cardiovascular diseases, increasing awareness about minimally invasive treatment options, and the well-established healthcare infrastructure. The expanding patient pool is leading to the growing focus on improving healthcare accessibility. Additionally, the rising advancements in medical technologies and favorable government initiatives will accelerate the regional product demand.